This announcement contains inside information for the purposes of Article 7 of theUK version of Regulation (EU) No 596/2014 which is part ofUK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 13 June 2024 ACUITY RM GROUP PLC ("Group" or the "Company") Final results for the year ended 31 December 2023 Acuity RM Group plc(AIM: ACRM) is pleased to announce its final results for the year ended 31 December 2023 Highlights · In the year the Company acquired the remaining shares in Acuity Risk Management Limited ("Acuity") that it did not already own · Acuity is the award winning risk management cybersecurity software company that owns the STREAM® brand with applications in the growing GRC sector · Post acquisition the focus has been to increase the pace of expansion of Acuity - the success of which has been evidenced by strengthening Key Performance Indicators (KPIs) as follows: · Sales pipeline has grown to £7.9m (£4.2m 2023) 88% growth · Orders won at annual contract value £1.6m (£1.1m 2023) 45% growth · Forward contracted revenues £2.9m (£2.2m 2023) 34% growth · Two largest contracts won · Developing Partner programme with 15 active partners to accelerate growth in the US and other key markets · Recruitment to strengthen Acuity's management team to enable fast growth · Finance and Technical directors · Sales and marketing executives · On 12 June 2024 the Group had Cash balances of £787,110 and current debtors £353,845 Angus Forrest, Chief Executive commented on the results: "This was a year of transformation for the Company. It acquired, Acuity, a software company which it knows and understands, having been an investor for the past two and a half years, during which it has grown consistently. We believe there are opportunities to accelerate that growth, the value of the business and shareholder value. Since acquisition this has been evidenced by the KPIs shown above." For further information: Acuity RM Group plc 020 3582 0566 Angus Forrest, www.acuityrmgroup.com Executive Chairman WH Ireland (NOMAD & https://www.whirelandplc.com/capital-markets Joint Broker) Mike Coe / Sarah 020 7220 1666 Mather Peterhouse Capital Limited (Joint Broker) Lucy Williams / Duncan 020 7469 0936 Vasey Clear Capital Markets 020 3869 6080 Limited (Joint Broker) Bob Roberts Chairman's Statement I am pleased to present the results of Acuity RM Group plc ("Company" or "Group") for the period ended 31 December 2023. 2023 was a year of significant change for the Group in which it acquired the remaining shares in Acuity Risk Management Limited (Acuity RM), which it did not already own (previously a 25% shareholding). As a result of this transaction, the Group's status changed from an investing to a trading company which should offer benefits for Acuity RM's trading: · the higher profile of a public company and as a plc similar to the majority of its customers; and · easier access to finance and at a lower cost, as well as the opportunity to use its shares as a currency; and for the Group's shareholders: · trading companies are usually valued on a more attractive basis, a multiple of trading metrics, than investing companies whose valuation typically is a discount to net asset value. A transaction such as the acquisition of Acuity RM takes up much management time and attention so is disruptive to the underlying business. I would like to thank Simon Marvell and Richard Mayall, founders and senior directors of Acuity RM, for their support. In the second half of the year new management appointments were made to strengthen the team and provide additional resource to grow the business. Acuity RM won its two largest contracts ever and made significant progress in putting in the infrastructure to facilitate further and faster growth. This will require further investment in 2024 and 2025 to enable it to increase customer numbers and average order value which, in turn, should be reflected in a higher valuation for the business. More detail about Acuity RM and its progress are included in the Chief Executive's report. The Group's results for the year ended 31 December 2023 reflect the acquisition of the share capital in Acuity RM not already owned by the Group. In 2022, the 25% stake in Acuity RM was shown as an investment, and for the year ended 2023 the results of Acuity RM have been consolidated from the date of acquisition, 25 April 2023. Board changes There have been several Board changes during the year. Simon Marvell who co -founded Acuity RM, joined the Group Board on the acquisition of Acuity RM and then retired on 27 June and resigned as a director. The Board would like to acknowledge his contribution to Acuity RM over many years. Even though Simon is now no longer involved in the day to day running of Acuity RM, he has remained as a consultant and non-executive board member of Acuity RM, so it continues to benefit from his knowledge and years of experience. Simon Bennett, who served as a director over three years, retired having overseen the acquisition and the Company's change from an investing to a trading company. The Board would like to thank Simon Marvell and Simon Bennett for their contributions and wishes them well for the future. Kerry Chambers who had been Commercial Director of Acuity RM for two years stepped up to become Chief Executive of Acuity RM and a Group Board director on 3 July. Outlook Acuity RM operates in a large, high growth market with customers in theUK ,North America andGermany as well as other territories and is successfully winning new contracts with key customers and forging relationships with partners to accelerate future growth. I would like to thank all shareholders for their continuing support and our advisers who made significant contributions to the major achievements in the year. I look forward to reporting further progress over the coming months. Shareholders can stay informed by visiting the Group website www.Acuityrmgroup.com . Chief Executive's Report Overview I am delighted to report on Acuity RM's performance for the period ended 31 December 2023, following its acquisition by Acuity RM Group plc. The names of both companies are now aligned with the underlying business. Reflecting on our achievements since assuming the role of CEO, Acuity RM, in July 2023, I am immensely proud of the strategic investments we have made to position our company for sustainable growth and success. We are excited about the potential for growth in global markets. We already have proven success with high-profile private and public sector clients worldwide in highly regulated and targeted industries and are well positioned to expand on this. Operating review Acuity offers an award-winning risk management software platform called STREAM® used for enterprise risk and assurance management. Organisations use it to identify and manage key risks while ensuring compliance with regulations, standards, and contracts. STREAM® is configured to manage certain risks, it collates and analyses all data relating to each risk in real time and provides alerts and alarms for managers to take action when performance deviates from acceptable standards. Implementing STREAM® is quick and easy, with either preconfigured set-ups or custom set up. It enables strategic decision-making, prioritisation of resources and justification of expenditure. Acuity has proven success supporting customers worldwide in highly regulated industries. The platform is sold in the Governance, Risk, and Compliance (GRC) market, where it ranks among the top GRC products in Gartner's Peer Insights. It scores highly in all categories and has 100% of peers recommending it. The GRC market was worth$14.9bn in 2022 (MarketsandMarkets) and is growing strongly. It is driven by legislation, regulation and best practice. In the second half of 2023 having identified the key areas for change and investment essential to improve our performance, maintain our technical prowess and grow our customers, orders and revenues, I initiated several changes including: Technical - recruitment of a new Chief Technology Officer (CTO) who has reviewed our IT technologies and is preparing for a comprehensive software re-write to add new features and improve efficiencies whilst ensuring that the STREAM platform remains at the forefront of GRC technology and maintains the platform's functionality and configurability. Sales and Marketing - there has been a recruitment campaign to increase internal sales and marketing capability as well as supporting and intensifying our partner programme, a cornerstone of our growth strategy. The focus is on growth: (1) upsell to existing customers, (2) new customers and higher value per contract. I am pleased to report that Acuity RM won its two largest orders in 2023 each valued at c. £500,000. I believe these actions represent an important investment in our future, positioning us to capitalise on emerging opportunities and navigate evolving market dynamics. Whilst we continue to demonstrate growth, revenues increased by 14% during the period 1 April 2023 to 31 December 2023 (on an annualised basis compared to the 12 months ended March 2023, Acuity RM's previous financial year end). I am delighted that the following Alternate Performance Indicators (APIs) for future performance demonstrate increasing strength: % increase 31 December 2023 31 March 2023 £'000 £'000 Forward contracted 32% 2,900 2,200 revenue 1 Orders won at annual 45% 1,600 1,100 contract value 2 Sales pipeline at 88% 7,900 4,200 annual contract value 3 The change of year end in order to make both companies' years co-terminus resulted in a nine month period for Acuity RM. 1 Forward contracted revenue is deferred income per the balance sheet and forward contracted revenue. Forward contracted revenue is not an IFRS measure. 2 Comparing the nine month period ended December 2023 with the same period in 2022. Orders at annual contract value is not an IFRS measure but is the basis for sales revenue. 3 Sales leads are included in the sales pipeline using an industry standard sales qualification methodology. Sales pipeline is not an IFRS measure We remain committed to innovation, growth, and delivering value to all our stakeholders. We are confident in our ability to seize opportunities, overcome challenges and drive sustainable growth. I would like to welcome the employees who joined us during the year and acknowledge the contribution of every employee and others who we work with. Information about the trading business and STREAM® is available on the Acuity RM website www.acuityrm.com . Group statement of comprehensive income for the year ended 31 December 2023 Notes Year Year ended 31 ended 31 December December 2022 2023 £'000 £'000 Continuing operations Revenue 1 1,366 60 Cost of sales (112) - Gross profit 1,254 60 Administrative expenses 2 & 3 (2,167) (316) Operating (loss) (913) (256) Finance Income 4 1 - Finance Expense 4 (20) - Loss on Investments 5 (66) (85) Exceptional costs 6 (282) - Share based payment expense 21 (61) Loss for the period before taxation (1,341) (341) Taxation 8 - - Loss for the year from continuing operations (1,341) (341) Other comprehensive income Total comprehensive income for the year (1,341) (341) attributable to shareholders of the parent company Earnings per share Basic and diluted earnings per share from 9 (1.39)p (0.81)p total and continuing operations The accompanying accounting policies and notes form an integral part of these consolidated financial statements. Group statement of financial position as at 31 December 2023 Notes As at 31 December 2023 As at 31 December £'000 2022 £'000 Non-current Assets Intangible assets 10 233 - Tangible assets 10 8 - Goodwill 11 5,154 - Investments at fair 12 244 930 value through profit or loss 5,639 930 Current assets Trade and other 14 1,255 122 receivables Cash and cash 100 222 equivalents 1,355 344 Total assets 6,994 1,274 LIABILITIES Current liabilities 16 557 47 Trade & other payables 17 1,016 - Deferred Income 17 165 - Loans & borrowings Tota Current liabilities 1,738 47 Long term liabilities 18 1,014 - Deferred Income 18 154 - Loans & borrowings Total long term 1,168 - liabilities Total Liabilities 2,906 47 Net Assets 4,088 1,227 EQUITY Share capital 19 2,767 2,688 Share premium 12,447 8,385 Share based payment 21 112 51 reserve Merger reserve 1,012 1,012 Retained earnings (12,250) (10,909) Total Equity 4,088 1,227 The consolidated financial statements were approved by the Board of Directors and authorised for issue on 12 June 2024. Group statement of changes in equity for the period ended 31 December 2023 Share Share Share based Merger Retained Total payment earnings capital premium Reserve reserve equity £'000 £'000 £'000 £'000 £'000 £'000 Balance at 1 2,688 8,385 30 1,012 (10,568) 1,547 January 2022 Loss for the - - - - (341) (341) year Total - - - - (341) (341) comprehensive expense for the year Transactions with owners in own capacity Issue of - - 21 - - 21 share options Balance at 31 2,688 8,385 51 1,012 (10,909) 1,227 December 2022 Balance at 1 2,688 8,385 51 1,012 (10,909) 1,227 January 2023 Loss for the - - - - (1,341) (1,341) year Other - - 61 - - 61 comprehensive income - issue of share warrants. Total - - 61 - (1,341) (1,280) comprehensive expense for the year Transactions with owners in own capacity Ordinary 78 4,375 - - - 4,453 Shares issued in the period Issue Shares 1 130 - - - 131 for adviser fees Share issue - (443) - - - (443) costs Transactions 79 4,062 - - - 4,141 with owners in own capacity Balance at 31 2,767 12,447 112 1,012 (12,250) 4,088 December 2023 Group statement of cash flows for the period ended 31 December 2023 As at 31 December As at 31 December 2023 2022 £'000 £'000 Cash flows from operating activities Loss before taxation (1,341) (341) Adjustments for: Depreciation & 137 - Amortisation Fair value adjustment for 61 85 listed investments Share based payments 61 21 (Increase) in trade and (823) (99) other receivables Increase/(Decrease) in 898 (5) trade and other payables Net cash outflow/inflow from (1,007) (339) operating activities Cash flows from investing activities Purchase of tangible fixed (3) - assets Purchase of investments in (500) - subsidiaries, net of cash acquired Cash acquired on acquisition 331 Net Cash flows used in (172) - investing activities Cash flows from financing activities Cash raised through issue of 1,057 - shares (net of transaction costs) Net cash flow from financing 1.057 - activity Net (decrease) in cash and cash (122) (339) equivalents Cash and cash equivalents at 222 561 the beginning of the period Cash and cash equivalents at 100 222 end of the year During the year there were the following material non-cash transactions: - On 25 April 2023 the Company issued 45,709,570 ordinary 0.1p shares to the shareholders of Acuity RM as part of the consideration for the acquisition. - On 25 April 2023 and 9 October 2023, the Company issued in total 1,642,539 ordinary 0.1p shares to the advisers as part payment for fees. The accompanying accounting policies and notes form an integral part of these consolidated financial statements. The accompanying accounting policies and notes form an integral part of these consolidated financial statements. Notes to the Financial Statements for the year ended 31 December 2023 1. Revenue and segmental analysis The following is an analysis of the Group's revenue for the year from continuing operations: Year ended 31 Year ended 31 December 2023 December 2023 £'000 £'000 Fees and Income from investee 15 60 companies Provision of software licences 1,351 - and Services consisting of: 1 revenue from subscriptions 1,114 revenue from services 237 The geographical analysis of revenue is as follows: United Kingdom 832 - Europe 220 - USA 165 - South Africa 52 - Canada 37 - Rest of World 45 - 1,351 - 1 Revenue from the subsidiary is included from acquisition date, 25 April 2023. 2. Administrative expenses Year ended 31 December 2023 Year ended 31 December 2022 £'000 £'000 Expenses by nature Staff and 1,286 149 related costs Professional 207 100 fees Office 104 15 related costs Depreciation 5 - Amortisation 133 - Software 88 - services Other 344 52 expenses Total 2,167 316 3. Staff Costs Year ended 31 December 2023 Year ended 31 December 2022 £'000 £'000 Staff costs - including directors Wages and 1,092 144 salaries National 127 5 insurance Other pension 40 - costs Other staff 27 - related costs 1,286 149 Year ended 31 Year ended 31 December 2023 December 2022 No. of No. of employees employees The average number of employees 23 5 (including Directors) of the Group was: Further details of individual Directors' remuneration, pension fund and interests in the Company are shown in the table on page 17. 4. Finance Costs Year ended 31 December 2023 Year ended 31 December 2022 £'000 £'000 Finance Costs Interest on (1) - bank deposits Bank 8 - Interest payable Other 12 - interest payable 19 - 5. Gain/Loss on remeasurement of financial assets and liabilities Year ended 31 Year ended 31 December 2022 December 2023 £'000 £'000 Loss on remeasurement of CBIL 5 - Loan Loss on revaluation of 61 85 investment in KCR Residential REIT plc 66 85 6. Exceptional costs Year ended 31 Year ended 31 December 2022 December 2023 £'000 £'000 Legal fees related to the 149 - acquisition of Acuity RM Other 133 - 282 - 7. Auditors' remuneration Year ended 31 Year ended 31 December 2022 December 2023 £'000 £'000 Auditor's remuneration 57 22 Transaction services in 100 - respect of the re-admission to AIM 157 22 8. Corporation tax There is no tax charge or credit for the current year. The tax assessed for the prior year is higher than the standard rate of corporation tax in theUK of 23.5% (2022: 19%). The differences are explained as follows: Year ended 31 December 2023 Year ended 31 December 2022 £'000 £'000 Loss on ordinary (1,341) (341) activities before taxation Loss on ordinary (315) (65) activities multiplied by standard rate of UK corporation tax of 23.5% (2022: 19%) Effect of: Disallowable items 62 20 Addition / 253 45 (utilisation) of tax losses arising Total tax - - charge/(credit) The Group has unrecognised deferred tax assets of £1,757,000 (2022: £1,504,000) as a result of losses in the current year and prior periods carried forward of £8,990,000 (2021: £8,013,000). 9. Earnings per ordinary share The calculation of basic and diluted earnings per share is calculated by dividing the profit or loss for the year by the weighted average number of ordinary shares in issue during the year. Year ended 31 Year ended 31 December 2022 December 2023 Loss attributable to (1,341) (341) equity shareholders (£'000) Weighted number of 96,242,220 41,982,024 ordinary shares in issue Loss per ordinary share (1.39)p (0.81)p 1 1 The 2022 loss per ordinary share is based on the post consolidation number of shares in issue. See note 18 for details. Diluted earnings per share has been calculated as the Group's average share price during the period is above the exercise price of one tranche of share options. However, as the options were exercisable from 25 November 2020 and using the treasury method to calculate diluted EPS, the impact was negligible and diluted earnings per share is equal to basic earnings per share. For the remaining share options and warrants, the Group's average share price during the period is lower than the exercise price of the share options and warrants and therefore the effect of including the share options and warrants is anti-dilutive. 10. Tangible and intangible assets - Group Group Group Group Group Group Tangible Software Customer Website Total Assets development contracts Intangible £'000 £'000 £'000 £'000 £'000 Cost or valuation At date of 30 670 227 37 934 acquisition 25 April 2023 Additions 3 0 0 0 0 C/F 31 December 33 670 227 37 934 2023 Accumulated depreciation At date of 20 331 208 29 568 acquisition 25 April 2023 Charge for year 5 106 19 8 133 C/F 31 December 25 437 227 37 701 2023 Net Book Value 31 8 233 0 0 233 December 2023 11. Goodwill Group Group 31 December 2023 31 December 2022 £'000 £'000 Goodwill arising on the 5,154 - acquisition of Acuity RM on 25 April 2023 The goodwill arises on the acquisition of Acuity RM in April 2023. The goodwill has been tested for impairment using a discounted cashflow forecast model. The model is for 5 years and uses a 10% growth rate on new sales and upsell reducing to 5% in the last year. The growth rate used in costs varies depending on the type of cost, with the biggest growth being employment costs as these are the most significant. The pre tax weighted average cost of capital used in the model was 5.07%. No impairment was deemed necessary at the reporting date. 12. Investments held at Fair Value through Profit and Loss Group Group Company Company 31 31 31 December 2023 31 December 2022 December December 2023 2022 £'000 £'000 £'000 £'000 Cost of investments B/F cost 2,330 2,330 2,330 2,330 Additions - - Transfer to (625) (625) investment in subsidiaries 1 C/F cost 1,705 2,330 1,705 2,330 Fair Value Movement B/F fair value (1,400) (1,315) (1,400) (1,315) Fair Value (61) (85) (61) (85) adjustment C/F Fair Value (1,461) (1,400) (1,461) (1,400) movement Fair Value of 244 930 244 930 Investments 1 Acuity RM Group plc previously held a 25% stake in Acuity RM. On 25 April 2023 it acquired 100% of the ordinary share capital of Acuity RM. The investment in Acuity RM has been transferred to an investment in subsidiary. See note 13. The Company acquired its legacy investment in KCR Residential REIT plc at a price of £0.70 per share in 2018. KCR is an AIM listed real estate investment trust focused on the residential property market. The investment was classed as fair value through profit and loss in accordance with IFRS 9. The share price at 31 December 2023 was £0.10 per share so the investment was valued downwards at the year-end by £61,143 in accordance with IFRS 13. The closing value at 31 December 2023 was £243,571. (31 December 2022: £304,714). Fair value hierarchy As KCR Residential REIT plc is an AIM listed company, it is measured under level 1 of the fair value hierarchy in accordance with IFRS 13: - Level 1: quoted prices in an active market for identical assets or liabilities. The fair value of financial instruments traded in active markets is based on quoted market prices at the balance sheet date. A market is regarded as active if quoted prices are readily and regularly available and those prices represent actual and regularly occurring market transactions on an arm's-length basis. The quoted market price used for financial assets held by the Group is the closing price on the last day of the financial year of the Group. These instruments are included in level 1 and comprise FTSE and AIM-listed investments classified as held at fair value through profit or loss. All assets held at fair value through profit or loss were designated as such upon initial recognition. 13. Investment in subsidiaries At 31 December 2023 the Company held 100% of the ordinary share capital of the following companies: Company Company 31 December 2023 31 December 2022 £'000 £'000 Investment in Acuity RM 25% investment in AcuityRM 1 625 625 Remaining 75% stake in AcuityRM 2 3,585 - C/F investment in Acuity RM 4,210 625 1 Prior to the acquisition of Acuity RM, the Company held a £625,000 investment in Acuity RM. This was shown as an investment at fair value through profit or loss- see note 12 2 On the 25 April 2023 the Company completed the successful acquisition of Acuity RM. The Company issued 45,709,570 ordinary shares and paid £500,000 in cash to acquire the remaining share capital of Acuity RM and now holds 100% of the share capital. Total value of consideration was £3.6m. In addition, Acuity RM Group plc held 100% of the ordinary share capital of World Life Sciences Ltd. It is a dormant company with a value of £nil and was dissolved on 12 March 2024. 14. Trade and Other Receivables Group Group Company Company 31 31 31 December 2023 31 December 2022 December December 2023 2022 £'000 £'000 £'000 £'000 Trade 1,093 12 - 12 Receivables Prepayments and 150 110 16 110 Accrued Income Other 12 - - - Receivables 1,255 122 16 122 15. Inter-Group Receivable Company Company 31 December 2023 31 December 2022 £'000 £'000 Inter-group loan - AcuityRM 1 392 - 1 The inter-group loan is repayable on demand 16. Trade and other payables Group Group Company Company 31 31 December 2022 31 December 2023 31 December 2022 December 2023 £'000 £'000 £'000 £'000 Trade 115 2 52 2 payables Employment 250 21 14 21 taxes and VAT Accruals 182 24 38 24 Other 10 - - - payables 557 47 104 47 17. Other current liabilities Group Group Company Company 31 31 December 2022 31 December 2023 31 December 2022 December 2023 £'000 £'000 £'000 £'000 Deferred 1,016 - - - Income Bank 68 - - - Loans 1 Other 97 - - - loans 1,181 18. Other non-current liabilities Group Group Company Company 31 31 December 2022 31 December 2023 31 December 2022 December 2023 £'000 £'000 £'000 £'000 Deferred 1,014 - - - Income Bank 154 - - - Loans 1 1,168 - - - 1 The bank loan is a CBIL that was taken out in July 2021. The loan is repayable over 6 years and is secured by a debenture. Under the terms of the CBIL no interest was payable for the first 12 months, therefore the CBIL has been fair valued through profit and loss. The fair value adjustment is disclosed in note 5. 19. Share capital Allotted, called up and fully paid Number of ordinary Year ended 31 December 2023 Year ended 31 December 2022 shares of 0.1p each B/F 419,822,048 419,822,048 Consolidation and (377,839,648) - subdivision 1 Shares issued 45,709,570 - during the year 2 Shares issued 32,222,222 - during the year 3 Shares issued 1,642,539 - during the year 4 C/f 121,556,731 419,822,048 1 On 24 April 2023 a resolution was approved by shareholders in a general meeting whereby the ordinary shares were subject to a consolidation and subdivision effectively reducing the number of shares and share options by a factor of 10. At the same time the number of deferred shares increased by 377,839,648. 2 On 25 April 2023 the Company issued 45,709,570 ordinary 0.1p shares to the shareholders of Acuity RM as part of the consideration for the acquisition. 3 On 25 April 2023 the Company issued 32,222,222 ordinary 0.1p shares to raise capital including, inter alia, £500,000 to pay the shareholder of Acuity RM as part of the consideration for the acquisition. 4 On 25 April 2023 and 9 October 2023 the Company issued in total 1,642,539 ordinary 0.1p shares to the advisers as part payment for fees. Year ended 31 Year ended 31 December 2022 December 2023 £'000 £'000 Allotted, called up and fully paid 121,556,731 (2022: 419,822,048) 121 420 ordinary shares of 0.1p each 2,645,954,765 (2022: 2,646 2,268 2,268,113,165) deferred shares of 0.1p each 2,767 2,688 20. Deferred shares On 24 April 2023 at the General Meeting of the Ordinary Shareholders a resolution to consolidate and subdivide the Ordinary shares was approved. The effect of this was to reduce the number of Ordinary shares in issueon the basis of 1 for 10 but the underlying assets remain at the same value so assets per shareincreased tenfold;and to create additional Deferred Shares which are effectively valueless. The other rights of the deferred shares are: ·no right to any dividend; ·the right to receive notice of any general meeting and to attend such meeting but no right to vote thereat. 21. Share options and warrants The Group operates an unapproved share option scheme. Awards under each scheme are made periodically to employees. The share options in this scheme vest three years after the date of grant and have an exercise period of seven years. The options may only be exercised by option holders while they are still employees of the Group. If death in service occurs the options can be exercised (to the extent that they have vested) by the option holder's personal representatives within 12 months from the date of death. If an option holder ceases to be employed and the Directors deem the option holder to be a `Good Leaver' the options can be exercised (to the extent that they have vested) within six months from the date of cessation of employment. A reconciliation of share option movements over the year ended 31 December 2023 is shown below: Number Outstanding at 31 December 2022 and 31 December 2023 1,500,000 At 31 December 2023 outstanding options granted over ordinary shares, adjusted for the share reorganisation in April 23 were as follows: Share Exercise Number Date granted Dates Exercisable option price scheme Company 6.5p 1,100,000 15 July 2020 15 July 2023 to 14 July 2030 unapproved Company 5.5p 400,000 25 Nov 2020 25 Nov 2023 to 24 Nov 2030 unapproved Further details on the share options can be found in the Remuneration Report on page 18. The weighted average exercise price for the Group's options are as follows: Options outstanding at 31 December 2023:6.2p Options exercisable at 31 December 2023:1,500,000 The weighted average remaining contractual life of the share options outstanding at the end of the year is 6 years (2022: 7 years). The Group has used the Black-Scholes formula to calculate the fair value of outstanding share options. The assumptions applied to the Black-Scholes formula for share options issued and the fair value per option are detailed in the table below for options issued. The charge calculated up to 31 December 2023 is £nil (2022: £21,000). Volatility was calculated using historical share price information for the six months prior to the date of grant. Unapproved share options 2020 grant Date of grant 15 July 2020 Expected life of options based on 3 years options exercised to date Volatility of share price 87% Dividend yield 0% Risk free interest rate 0.01% Share price at date of grant - 6.5p adjusted for share reorganisation April 2023 Exercise price - adjusted for share 6.5p reorganisation April 2023 Fair value per option - adjusted for 4.6p share reorganisation April 2023 Date of grant 25 Nov 2020 Expected life of options based on 3 years options exercised to date Volatility of share price 96% Dividend yield 0% Risk free interest rate 0.01% Share price at date of grant - 4.8p adjusted for share reorganisation April 2023 Exercise price - adjusted for share 5.5p reorganisation April 2023 Fair value per option - adjusted for 3.5p share reorganisation April 2023 Warrants On 25 April, in connection with the acquisition of Acuity RM, the Company issued certain advisers with warrants to subscribe for the number of shares shown below at a price of4.5 pence per share. The first date of exercise to be 25 April 2024 and the warrants expire on 24 April 2026. Share Exercise Number Date Dates Exercisable Warrant price granted Holders Clear 4.5p 1,674,465 25 25 April 2024 - 24 April 2026 Capital April Markets Ltd 2023 Peterhouse 4.5p 475,534 25 25 April 2024 - 24 April 2026 Capital Ltd April 2023 Warrants exercisable at 31 December 2023: nil The Group has used the Black-Scholes formula to calculate the fair value of outstanding share options. The assumptions applied to the Black-Scholes formula for share warrants issued and the fair value per warrant are detailed in the table below for warrants issued. The charge calculated up to 31 December 2023 is £61,000 (2022: £nil). Date of grant 25 April 2023 Expected life of the Warrants 3 years Volatility of share price 60.2% Dividend yield 0% Risk free interest rate 3.67% Share price at 31 December 2023 6.0p Exercise price 4.5p Fair value per option - adjusted 3.1p for share reorganisation April 2023 22. Pensions The Group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Group in an independently administered fund. Employer contributions for the year were £39,999. Contributions payable to the pension scheme are charged to the income statement in the year to which they relate. The Group has no further payment obligations once the contributions have been paid. 23. Transactions with related parties Group and Company The key management personnel of the Company are considered to be the Directors. Acuity RM Limited, a 100% owned subsidiary, was charged £45,000 for management fees for the period ended 31 December 2023. (12 months ended March 2023: £60,000). At the end December 2023 Acuity RM owed £75,000 plus VAT for unpaid management fees (March 2023: £25,000 plus VAT). These amounts form part of the inter group balance between the Company and Acuity RM. 24. Business combinations On the 25 April 2023 the Company completed the successful acquisition of Acuity RM. The Company issued 45,709,570 ordinary shares and paid £500,000 in cash to acquire the remaining share capital of Acuity RM and now holds 100% of the share capital. Total value of consideration was £3.6m. Prior to the acquisition of Acuity RM, the Company held a £625,000 investment in Acuity RM. Consideration £'000 B/f cost of 25% stake in Acuity Ltd 625 acquired in 2020 Consideration to acquire remaining share capital of Acuity RM on 25 April 2023 Issue of ordinary shares 3,085 Cash consideration 500 Total consideration 4,210 Management have undertaken a purchase price allocation exercise to assess the value of the net assets acquired on acquisition. Management have concluded that the fair value of the net assets acquired is equal to the book value, with the difference between the consideration paid and the nets assets being allocated to goodwill - see below. The value of the goodwill represents Acuity RM's effective approach to risk assurance, their know how and technical understanding of the market and deep customer relationships which are all driven by a strong assembled workforce. The goodwill has been tested for impairment at the reporting date as described in note 11. Recognised amounts of Book Value Fair Value Adjustments Total assets and liabilities acquired £'000 £'000 £'000 Goodwill 1,673 (1,673) - Capitalised software 338 338 Other fixed assets 37 37 Trade and other 310 310 receivables Cash 331 331 Trade and other payables (327) (327) Deferred Income (1,369) (1,369) Borrowings (264) (264) Total identifiable net 729 (1,673) (944) assets Goodwill 5,154 Total consideration 4,210 Since 25 April 2023, Acuity RM has contributed a loss of £709,614 and revenue of £1,351,185. Had Acuity RM been consolidated from 1 January 2023 it would show an additional loss of £175,048 and revenue of £614,697. 25. Financial instruments and risk profile The Group's and Company's financial instruments comprises investment, cash balances, debtors and creditors that arise directly from its operations and derivative instruments. The Group and Company are exposed to risk through the use of financial instruments and specifically to liquidity and market price risk and foreign exchange rate risks, which result from the Group's operating activities. The Board's policy for managing these risks is summarised below. Liquidity and market price risks The Group currently has an investment in KCR Residential REIT plc. Although this is a traded investment it has limited liquidity. The Group and Company are exposed to market price risk as shown by movements in the value of its equity investment. Any such risk is regularly monitored bytheDirectors. Foreign exchange rate risks Acuity RM trades overseas and invoices in the local currency in territories with currencies traded in major markets, but in less developed areas it will invoice in £ Sterling or other major currency as agreed with the customer. Capital risk management The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders, benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. The Group monitors capital on the basis of the carrying amount of equity, less cash and cash equivalents as presented on the face of the Statement of financial position. The movement in the capital to overall financing ratio is shown below: Group Group Company Company 31 31 31 December 2023 31 December 2022 December December 2023 2022 £'000 £'000 £'000 £'000 Equity 4,088 1,227 4,798 1,227 Less: cash and (100) (222) (40) (222) cash equivalents Capital 3,988 1,005 4,758 1,005 Equity 4,088 1,227 4,798 1,227 Borrowings 319 - - - Overall 4,407 1,227 4,798 1,227 financing Capital to 90.5% 81.9% 99.2% 81.9% overall financing In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. Credit risk The Group's exposure to credit risk is limited to the carrying amount of financial assets recognised at the balance sheet date. Group Group Company Company 31 31 December 2022 31 December 2023 31 December 2022 December 2023 £'000 £'000 £'000 £'000 Trade and 1,255 122 16 122 other receivables Cash and cash 100 222 40 222 equivalents Inter group - - 392 - loan 1,355 344 448 344 The Directors consider that all the above financial assets are of reasonable quality. No amounts shown above are considered to be past their duedate. Summary of financial assets and liabilities by category The carrying amount of financial assets and liabilities as recognised at the balance sheet date of the reporting periods under review may also becategorised as below: Group Group Company Company 31 31 31 31 December 2022 December December December 2023 2022 2023 £'000 £'000 £'000 £'000 Current assets Trade and other 1,255 122 16 122 receivables Cash and cash 100 222 40 222 equivalents Inter group loan - - 392 Financial assets at 1,355 344 448 344 amortised cost Financial assets at 244 930 244 930 FVTPL Current liabilities Trade and other 557 47 - 47 payables Deferred income 1,016 - - Loans 68 - - Financial liabilities 1,641 47 - 47 carried at amortised cost Financial liabilities 97 - - - carried at FVTPL Non current liabilities Deferred Income 1,014 - - - Financial liabilities 1,014 - - - carried at amortised cost Financial liabilities 154 - - - carried at FVTPL The financial instruments held at fair value through profit or loss have been valued in accordance with IFRS 13. In the current year, these are determined by reference to quoted prices where there is an active market for identical assets or liabilities. Otherwise, the fair value is determined by using valuation techniques such as earnings multiples. There is no material difference between the carrying value and fair value of the Group's aggregate financial assets and liabilities. Interest rate risk profile of financial liabilities Group Group Company Company 31 31 31 31 December 2022 December December December 2023 2022 2023 £'000 £'000 £'000 £'000 Floating rate financial - - - - liabilities Fixed rate financial 319 - - - liabilities Financial liabilities on 2,587 47 104 47 which no interest is paid 2,906 47 104 47 26. Subsidiary undertakings At 31 December 2023 the Group held 100% of the equity of the following: Company name Country of Principal activity Holding Class of shares registration Acuity Risk England Software development 100% Ordinary Management Ltd World Life England Dormant 100% Ordinary Sciences Limited The registered address of the Acuity Risk Management Ltd is the same as that of the parent company see note 27. The registered address of World Life Sciences Limited is Burnham Yard,London End, Beaconsfield, HP9 2JH. It is a company with no assets and was dissolved in March 2024. 27. Company information The Company is a Public Limited Company registered inEngland andWales . The registered office is 2nd Floor, 80 Cheapside,London EC2V 6EE. 28. Ultimate controlling party The Directors believe that there is no overall controlling party of the Company. 29. Events after the balance sheet date There are no events after the reporting date to be disclosed. 30. Contingent Liabilities There are no contingent liabilities to be disclosed. This information was brought to you by Cision http://news.cision.com https://news.cision.com/acuity-rm-group-plc/r/annual-financial-report,c4000034
ACRM.L
Acuity RM Group Plc
Acuity RM Group Plc - Annual Financial Report
13th June 2024, 06:34
To continue viewing RNS, please confirm that you are a Private Investor*
* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
- Obtains access to the information in a personal capacity;
- Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
- Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
- Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
- Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
- Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.